Effect of esketamine for preventing postpartum depression in high risk population of postpartum depression after cesarean section: a randomized controlled trial

Effect of esketamine for preventing postpartum depression in high risk population of postpartum depression after cesarean section

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077191

Enrollment

Unknown

Registered

2023-11-01

Start date

2023-10-20

Completion date

Unknown

Last updated

2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Depression

Interventions

Experimental group:Esketamine

Control group:Placebo

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Age 18-40 years old, 2.ASA level I-II, 3.Edinburgh Postnatal Depression Scale, EPDS = 10.

Exclusion criteria

Exclusion criteria: 1. The body mass index = 40 kg/m2 2. History of mental illness 3. Severe obstetric complications or severe underlying diseases 4. A history of allergy to Esketamine or contraindications for spinal anesthesia.

Design outcomes

Secondary

Measure	Time frame
NRS scores at different time after surgery;Consumption of sufentani;	—

Primary

Measure	Time frame
incidence of postpartum depression;	—

Countries

China

Contacts

Public ContactQing-ren Liu

Wuxi Xishan People's Hospital, Jiangsu Province, China

Liuqr5250@163.com+86 136 0151 0412

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026